Amir Belson, M.D.
Prior to conceiving of and starting ZipLine Medical, Amir Belson, M.D. founded NeoGuide Systems, a company that developed a platform technology for minimally invasive surgical procedures. NeoGuide was acquired by Intuitive Surgical in 2009. Dr. Belson founded Vascular Pathways, a company that developed an FDA cleared vascular intervention technology that has been chosen as one of the 10 best inventions of 2009 by Popular Science magazine. Vascular Pathways was acquired by C.R. Bard in 2015. Dr. Belson also founded Qool, which is developing innovative therapeutic hypothermia technology, Radiaction, which is developing radiation protection for healthcare providers, and Emboline, which is developing emolic protection technology for TAVI and other interventional cardiology procedures.
Dr. Belson graduated cum laude from the school of medicine of the Technion, Israel Institute of Technology, in Haifa, Israel. He completed his pediatric residency at Dana Children’s Hospital in Tel Aviv and his pediatric nephrology fellowship at Lucile Packard Children’s Hospital at Stanford University. He also served several years as a flight surgeon in the IDF air force rescue unit before moving to the US for a three year Pediatric Nephrology fellowship at Stanford University Medical Center. Dr. Belson also spent one year as a research fellow with the Biomedical Technology Innovation Program at Stanford.
Ted Driscoll, Ph.D.
Ted Driscoll is a Venture Partner at Claremont Creek Ventures and brings 30 years of experience in health and imaging technology as an investor and entrepreneur. Ted is an expert on digital health and diagnostics, from big data and health technology to genomics and personalized medicine.
Ted has a successful track record of sourcing and leading the financing of promising digital healthcare startup companies, including Natera, GeneWeave and Numedii. Ted currently represents CCV on the boards of Natera, AssureX, Numedii, Zipline Medical, GeneWeave BioSciences, Prime Genomics and Gigagen. He also served as a board member of Tibion (acquired by AlterG).
Prior to Claremont Creek, Ted founded five successful companies in imaging-related markets. He was founder and CEO of Be Here Technologies, a pioneer in Internet, Broadcast and Videoconferencing technologies. He also served as CEO of Focus Surgery, spun off from Diasonics, and was previously Division President and CTO of Diasonics, with responsibility for its MRI, ultrasound, digital X-ray, and ablation technology business. Earlier, he led the Diasonics team that developed the first commercial MRI scanners. Previously, Ted was also Vice President of Engineering at Identix, then a world leader in fingerprint recognition; and was Director of R&D at International Imaging Systems, an early pioneer in satellite remote sensing.
Ted was an angel investor with Life Science Angels and a founding director of the Sand Hill Angels and Health Tech Capital. Ted holds a PhD from Stanford University in Digital Imaging, Masters degrees from Harvard University in Computer Graphics and Remote Sensing and a Bachelor’s degree from the University of Pennsylvania. Ted holds 40+ granted US and foreign patents in imaging-related fields.
Bali Muralidhar, M.D. Ph.D.
Bali joined MVM in 2012. Before joining he was a key member of Bain Capital’s healthcare deal team. Prior to that, he was a management consultant in Bain & Company’s healthcare team. Bali obtained a degree in Clinical Medicine from Oxford University and practiced general surgery at the John Radcliffe and Addenbrooke’s Hospitals. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, Cambridge University, and has published over a dozen peer reviewed papers.
Bali is a member of the boards of Onbone Oy, Wilson Therapeutics AB and Zipline Medical, Inc.
Stephen Reeders, M.D.
Steve founded MVM in 1997. Prior to setting up MVM, he was responsible for early-stage healthcare investments at Saunders, Karp & Megrue in New York City. Between 1988 and 1993 Steve was an Investigator of the Howard Hughes Medical Institute at the Boyer Center for Molecular Medicine at Yale, where he was also an Associate Professor of Medicine and Genetics. He has published more than 50 papers on the molecular genetics of human disease.
Steve has been involved in starting several US biotechnology companies and was acting CEO at UpToDate In Medicine in Wellesley, Mass. He practised medicine at the John Radcliffe Hospital, Churchill Hospital, Guys Hospital, St Thomas’s Hospital, Hammersmith Hospital and the Institute of Neurology, Queen Square before taking up research into molecular genetics at Oxford University. He has a degree in Natural Sciences from Cambridge and a Doctorate in medicine from Oxford and is a member of the Royal College of Physicians of England.
Steve is a member of the boards of Ambio, Inc., Cheetah Medical, Inc., Pulmagen Therapeutics Ltd and Zipline Medical, Inc. He was previously a director of Beacon Endoscopic Ltd, BioVex Group, Inc., Cara Therapeutics, Inc., Clavis Pharma ASA, Domantis Ltd, Gendaq Ltd, Momenta Pharmaceuticals, Inc., New Chemical Entities, Inc., Nova Science Ltd, Sangamo Biosciences, Inc., UpToDate, Inc., Xention Ltd and Vascular Pathways, Inc.
John R. Tighe
John R. Tighe serves as Chief Executive Officer and president of ZipLine Medical, Inc. He also serves as a member of ZipLine’s board of directors. Prior to joining ZipLine, he was the CEO and president of PEAK Surgical, Inc. from 2006 to 2011. He was the first employee and also served as a Director of PEAK Surgical until their acquisition by Medtronic in 2011. Mr. Tighe has over 22 years of experience in the medical device industry and has worldwide commercialization experience in several medical specialties, including orthopaedics, ENT, and general surgery. Prior to PEAK Surgical he was senior vice president and general manager of all business units for ArthroCare Corporation, where he worked for 11 years. Before that, he served as national sales manager for Acufex Microsurgical, where he worked in various sales and management roles over a seven year period. Mr. Tighe holds a B.S. degree in Civil Engineering from the University of Maryland.
Dean Tozer has more than 25 years of experience in the global healthcare industry with an established track record of successfully launching and marketing innovative technologies. Mr. Tozer currently works as a consultant/advisor in the field of commercial and corporate strategy. His clients include HighCape portfolio companies as well as other commercial-stage start-up organizations.
Prior to his current role, he was President & CEO of Nuo Therapeutics, a biomedical company that markets innovative wound care products. He joined Nuo following his tenure as Vice President of Corporate Development for Shire Regenerative Medicine, where he led business development efforts for that division, including the 2012 acquisition of Pervasis Therapeutics. Tozer arrived at Shire through the 2011 acquisition of Advanced BioHealing, where he was Senior Vice President since the company’s inception in 2006. He is widely regarded as a key architect of the commercial strategy behind the re-launch and subsequent success of Dermagraft in the U.S. market.
Prior to working with early stage companies, he spent 10 years in the global pharmaceutical industry and lived in Toronto, Chicago and Tokyo while commercializing global blockbuster products such as Bextra & Celebrex.
From 2009 to 2013, Mr. Tozer also served as a founding executive and officer of The Alliance for Regenerative Medicine. He received a Bachelor of Commerce degree from Saint Mary’s University in Halifax, Nova Scotia and a Certified Management Accountant designation in Ontario, Canada.